FDA 因 GLP-1 受体激动剂潜在增加罕见但严重眼部疾病风险要求安全性标签变更(2026-11-09)
Drug Safety Communications
FDA 于 2026-11-09 要求对胰高血糖素样肽-1 受体激动剂(GLP-1 RAs)进行安全性标签变更,原因是该类药品可能增加罕见但严重的眼部疾病风险。同日发布的药物安全通讯列表还收录了 2026 年其他标签安全更新,包括 Kybella(脱氧胆酸)注射剂非批准用途不良反应警示及 Injectafer(羧基麦芽糖铁注射液)低磷血症黑框警告。
Español 药物安全通讯 Drug Safety Podcasts
FDA Drug Safety Communications are intended to provide important information to patients and health care professionals about new safety issues with the medicines they are taking or prescribing so they can make more informed decisions about treatment.
Widespread or long-term use of drugs by patients may uncover side effects not discovered during the clinical trials a drug company did to get FDA approval of the medicine. As a result, FDA physicians and scientists continue to monitor the safety of drugs after they are approved. When we learn information about a potential new safety issue, we review the data from available clinical trials or other studies, case reports, and medical literature. Based on what we find, we may require changes to the prescribing information or the patient Medication Guide. We may also release a Drug Safety Communication to alert patients and health care professionals about the issue. Read more.
You can get new safety information on medicines you’re prescribing or taking by signing up for email alerts about Drug Safety Communications on types of drugs or medical specialties of specific interest to you.
Drug Safety Communications
Resources
- Full archived versions of Drug Safety Communications published before 2020
- Development & Approval Process (Drugs)
- How Drugs are Developed and Approved
- FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective
- Think It Through: Managing the Benefits and Risks of Medicines
- Overview of our role regulating and approving drugs | Video series
- Drugs@FDA: FDA-Approved Drugs
- Find Information about a Drug
来源:FDA 官方药品与生物制品信息 · fda.gov